ReviewJournal of nanobiotechnology2025
Nanomedicine in cardiovascular and cerebrovascular diseases: targeted nanozyme therapies and their clinical potential and current challenges.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Advances in ultrasound-mediated nanozyme systems in therapeutic applications.Ultrasonics sonochemistry · 2026Review
- Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Breaking Biological Barriers: Engineering Nanocarriers for Efficient Drug and Gene Delivery through Nano-Bio Interfaces and Biophysical Design.Applied physics reviews · 2026Article
- Engineering nanozymes for cancer theranostics: Chemical design, catalytic intelligence, and translational oncology frontiers.Translational oncology · 2026Review
- Endogenous near-infrared chemiluminescent manganese ion-driven porphyrin supramolecular platform for the theranostics of thrombosis and ischemic stroke.RSC advances · 2026Article
- Macrophage immunometabolism in stroke: a view from single-cell and nano technologies.Journal of translational medicine · 2026Review
- Programming the beating heart with polymer catalysis: a therapeutic microenvironment revolution.Journal of nanobiotechnology · 2026Review
- Myocardial Ischemia-Reperfusion Injury-Mechanistic Insights and Novel Therapeutics.International journal of molecular sciences · 2026Review
- Neuroprotective Nanoplatform Integrating Antioxidant MXene Nanozymes and Ferroptosis Inhibitors for Targeted Therapy of Cerebral Ischemia-Reperfusion Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanomaterials and exercise interventions: A synergistic approach for atherosclerosis therapy (Review).International journal of molecular medicine · 2026Review
- Nanozyme-Based Anti-Inflammatory Strategies in Cardiovascular Disease Management: Clinical Prospects and Challenges.International journal of nanomedicine · 2026Review
- Oxidoreductase-Like Nanozymes: From Biosensing to Molecular Mechanisms in Disease Therapy.International journal of nanomedicine · 2026Review
- Beyond Lipids and Platelets: A Review of Anti-Inflammatory Strategies in Secondary Prevention of Acute Coronary Syndromes.Journal of clinical medicine · 2025Review
- Radioprotection redefined: drug discovery at the intersection of tardigrade biology and translational pharmacology.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular and cerebrovascular diseases continue to be significant public health problems, with high mortality and morbidity rates worldwide. Inflammation and ROS are believed to be the hallmarks of these diseases, but conventional therapies targeting inflammation and ROS have had limited success due to their limited pharmacokinetics, low bioavailability, shorter half-life, and notable side effects. Over the last decade, nanomedicine has rapidly evolved with diverse applications in diagnostics, drug delivery, and treatment of various diseases, including cardiovascular and cerebrovascular diseases. Nanomaterials such as nanozymes have gained success with remarkable therapeutic efficacy due to their stability, formulations, enzyme-mimetic activities, and ability to deliver more than one drug. Moreover, nanozymes can uphold a constant rate of drug release, maintaining a low frequency of dosing to reduce the side effects of drugs. Due to their multifunctional nature, they can be used as targeted delivery vehicles to the damaged brain, arterial, and other tissues to mitigate inflammation and ROS while promoting blood-brain barrier protection, ischemic stroke neurovascular recovery, and neuronal cell survival. In this review article, we have explored the mechanisms and different types of nanozyme-based targeted therapies for several cardiovascular and cerebrovascular diseases, including myocardial infarction, atherosclerosis, and ischemic stroke. We have discussed their enzyme-mimetic catalytic activities, immune-modulatory effects, ROS scavenging abilities, and anti-inflammatory properties. We have also discussed the challenges that slow down the clinical and translational success of these nanozyme-based therapies. Continuing work with integrated and multidisciplinary approaches, these nanozymes may offer potential solutions for cardiovascular and cerebrovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.